FRAX-based assessment and intervention thresholds—an exploration of thresholds in women aged 50 years and older in the UK

Osteoporosis International

Volumn 26, Issue 8, 2015, Pages 2091-2099

  McCloskey, E ^a   Kanis, J A ^b   Johansson, H ^b   Harvey, N ^c   Oden A ^d   Cooper, A ^e   Cooper, C ^c,f   Francis, R M ^g   Reid, D M ^h   Marsh, D ⁱ   Selby, P ^j   Thompson, F ^k   Hewitt, S ^k   Compston, J ^l  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d Bridge Medical Centre ^*  (Sweden)

^e Bridge Medical Centre   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

^h UNIVERSITY OF ABERDEEN   (United Kingdom)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^k NATIONAL OSTEOPOROSIS SOCIETY   (United Kingdom)

^l UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

Assessment threshold; BMD; Fracture; FRAX; Intervention threshold; NOGG

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE DENSITY; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; EXPLORATORY RESEARCH; FEMALE; FRAX BASED ASSESSMENT; GROUPS BY AGE; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; INTERVENTION THRESHOLD; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; UNITED KINGDOM; VERY ELDERLY; AGE; COMPLICATION; HIP FRACTURES; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PATHOPHYSIOLOGY; PATIENT SELECTION; PHYSIOLOGY; PROCEDURES; RISK ASSESSMENT; SECONDARY PREVENTION;

BONE DENSITY CONSERVATION AGENT;

AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; HIP FRACTURES; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; UNITED KINGDOM;

EID: 84938962753     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-015-3176-0     Document Type: Article

References (21)

1. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24(23–57):23079689
2. Grigorie D, Sucaliuc A, Johansson H, Kanis JA, McCloskey E (2013) FRAX-based intervention and assessment thresholds for osteoporosis in Romania. Arch Osteoporos 8(164):24390553
3. Compston J, Bowring C, Cooper A et al (2013) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 75(392–396):23810490
4. Lekamwasam S (2013) Sri Lankan FRAX model and country-specific intervention thresholds. Arch Osteoporos 8(148):23975235
5. Tuzun S, Eskiyurt N, Akarirmak U, Saridogan M, Johansson H, McCloskey E, Kanis JA (2012) The impact of a FRAX-based intervention threshold in Turkey: the FRAX-TURK study. Arch Osteoporos 7(229–235):23060308
6. Lekamwasam S, Adachi JD, Agnusdei D et al (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23(2257–2276):22434203
7. National Institute for Health and Care Excellence (2012) NICE Clinical Guideline 146. Osteoporosis: assessing the risk of fragility fracture
8. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19(385–397):18292978
9. Hippisley-Cox J, Coupland C (2012) Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ 344(e3427):22619194
10. Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P, Wilkins M (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62(105–108):19135323
11. Bruyere O, Fossi M, Zegels B, Leonori L, Hiligsmann M, Neuprez A, Reginster JY (2013) Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria. Rheumatol Int 33(973–978):22842952
12. Briot K, Cortet B, Thomas T et al (2012) 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine 79(304–313):22521109
13. Johansson H, Oden A, Johnell O, Jonsson B, de Laet C, Oglesby A, McCloskey EV, Kayan K, Jalava T, Kanis JA (2004) Optimization of BMD measurements to identify high risk groups for treatment—a test analysis. J Bone Miner Res 19(906–913):15190881
14. Johansson H, Kanis JA, Oden A, Compston J, McCloskey E (2012) A comparison of case-finding strategies in the UK for the management of hip fractures. Osteoporos Int 23(907–915):22234810
15. NICE (2010) TA161 (amended) Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. National Institute for Health and Clinical Excellence
16. Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ 3rd (2010) The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int 21(41–52):19705046
17. Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 19(449–458):18292975
18. Hagino H (2014) Revised osteoporosis diagnostic criteria and Japanese practice guideline on osteoporosis. Clin Calcium 24:11–18, 24369275
19. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A (2008) Case finding for the management of osteoporosis with FRAX—assessment and intervention thresholds for the UK. Osteoporos Int 19(1395–1408):18751937
20. Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21(495–505):19565175
21. Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ 3rd (2012) The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005–2008. Osteoporos Int 23(811–820):21717247